Gang Wang

Director/Board Member presso SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

67 anni

Health Technology

Consumer Services

Profilo

Gang Wang is currently an Executive Director at Shanghai Junshi Biosciences Co., Ltd., an Independent Director at Hrain Biotechnology Co., Ltd., and an Independent Director at Obio Technology Shanghai Corp.
Ltd.
Dr. Wang obtained a doctorate degree from Dartmouth Medical School in 1995.

Posizioni attive di Gang Wang

Società	Posizione	Inizio
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	Director/Board Member	20/10/2023
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	Director/Board Member	29/12/2020
Hrain Biotechnology Co., Ltd. Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.	Director/Board Member	18/06/2021

Tutte le posizioni attive di Gang Wang

Formazione di Gang Wang

Dartmouth Medical School

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Gang Wang

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	Health Technology
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	Health Technology

Aziende private	1
Hrain Biotechnology Co., Ltd. Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.	Health Technology